← Back to Search


DWN12088 for Pulmonary Fibrosis

Inje University Busan Paik Hospital, Busan, Korea, Republic of
DWN12088 +1 morePhase 2RecruitingLed by JW SongResearch Sponsored by Daewoong Pharmaceutical Co. LTD.

Study Summary

This trial tests a new drug, DWN12088, to see if it is safe and effective for treating Idiopathic Pulmonary Fibrosis.

Eligible Conditions
  • Idiopathic Pulmonary Fibrosis

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You have been diagnosed with a lung disease called IPF according to certain guidelines from medical societies.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from day 1 through week 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and from day 1 through week 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidents of treatment-emergent adverse events
Rate of decline of FVC
Secondary outcome measures
Diffusing capacity of lung for carbon monoxide (DLCO) corrected for Hgb
Functional exercise capacity, assessed by the 6-minute walk test (6MWT) distance
Quantitative high-resolution computed tomography
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: DWN12088 Xmg Tablet (BID)Experimental Treatment1 Intervention
PRS inhibitor
Group II: Placebo 0mg Tablet (BID)Placebo Group1 Intervention
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1

Find a Location

Who is running the clinical trial?

Daewoong Pharmaceutical Co. LTD.Lead Sponsor
187 Previous Clinical Trials
155,065 Total Patients Enrolled
3 Trials studying Idiopathic Pulmonary Fibrosis
108 Patients Enrolled for Idiopathic Pulmonary Fibrosis
JW SongPrincipal InvestigatorAsan Medical Center
SongPrincipal InvestigatorAIDS Malignancy Consortium

Media Library

DWN12088 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05389215 — Phase 2
Idiopathic Pulmonary Fibrosis Research Study Groups: DWN12088 Xmg Tablet (BID), Placebo 0mg Tablet (BID)
Idiopathic Pulmonary Fibrosis Clinical Trial 2023: DWN12088 Highlights & Side Effects. Trial Name: NCT05389215 — Phase 2
DWN12088 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05389215 — Phase 2
Idiopathic Pulmonary Fibrosis Patient Testimony for trial: Trial Name: NCT05389215 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has DWN12088 been given the green light from the FDA?

"Due to the limited amount of evidence available for DWN12088's efficacy, it was given a safety ranking score of 2. However, there is some research that substantiates its safety."

Answered by AI

What are the desired outcomes of this clinical experiment?

"The principal objective of this medical trial, which will be monitored over the course of 24 weeks, is to establish a rate for Forced Vital Capacity (FVC) decrease. Additionally, Quantitative High-Resolution Computed Tomography (HRCT), Time To Progression Of Idiopathic Pulmonary Fibrosis (IPF), and Diffusing Capacity Of Lung For Carbon Monoxide Corrected By Haemoglobin levels will also be tracked as secondary objectives."

Answered by AI

Is this investigation accepting new recruits?

"Unfortunately, according to the details posted on clinicaltrials.gov, this particular medical trial is no longer recruiting participants; it was initially published on August 30th 2022 and last updated July 25th 2022. However, fortunately there are currently 410 other studies actively enrolling patients at this time."

Answered by AI

Who else is applying?

What state do they live in?
New York
What site did they apply to?
Daewoong Investigator site
University of Kansas Medical Center Research Institute, Inc
Lowcountry Lung and Critical Care
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?

Why did patients apply to this trial?

i tried nintedanib for three months but it does not work.
PatientReceived 1 prior treatment
~27 spots leftby Jun 2024